Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Safety, Pharmacodynamic, and Anti-Tumor Activity of SL-172154 As Monotherapy and in Combination with Azacitidine (AZA) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) Patients (pts)

Naval Daver, Anthony Selwyn Stein, Dale Bixby, Wanxing Chai-Ho, Joshua F. Zeidner, Keri Maher, Don A. Stevens, Maximilian Stahl, Karen Yee, Emily K Curran, Sawa Ito, Andrew Sochacki, David A Sallman, Robert Hernandez, Simon Metenou, Bo Ma, Kazunobu Kato, Amer M. Zeidan

Blood (2023) 142 (Supplement 1): 4278.

https://doi.org/10.1182/blood-2023-173991

Published: 2023

Journal Articles

Integrating Mosaic Chromosomal Alterations and Single-Nucleotide Variants to Predict Evolution of Clonal Hematopoiesis

Ashwin Kishtagari, MA Wasay Khan, Yajing Li, Cosmin Bejan, Naimisha Marneni, Alexander J. Silver, Kelly von Beck, Travis Spaulding, Shannon Stockton, Christina A. Snider, Kelly Pugh, Andrew Sochacki, Dixon Dorand, Taralynn Mack, Caitlyn Vlasschaert, Brent Ferrell, Yaomin Xu, Michael R. Savona, Alexander G. Bick

Blood (2022) 140 (Supplement 1): 2868–2870.

https://doi.org/10.1182/blood-2022-170957

Published: 2022

Journal Articles

Patient-Specific Risk Factors Independently Influence Survival in Myelodysplastic Syndromes in an Unbiased Review of EHR Records

Travis Spaulding, MD, Nicholas Strayer, Andrew Sochacki, MD, Shannon Stockton, MD, Alexander Silver, Rodney Dixon Dorand, MD PhD, Siwei Zhang, PhD, Ya-Chen Lin, Yaomin Xu, PhD, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 5440.

https://doi.org/10.1182/blood-2019-122400

Published: 2019

Journal Articles

JAK2 V617F Clonal Hematopoiesis Stratifies By Peripheral Blood Counts.

Andrew Sochacki, MD, Shilin Zhao, PhD, Cosmin Adrian Bejan, PhD, Travis Spaulding, MD, Shannon Stockton, MD, Alexander Silver, Dixon Dorand, MD PhD, Siwei Zhang, PhD, Thomas Stricker, MD PhD, Yaomin Xu, PhD, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 1203.

https://doi.org/10.1182/blood-2019-129639

Published: 2019

Journal Articles

Patient Specific Comorbidities Impact Overall Survival in Myelofibrosis

Andrew Sochacki, MD, Cosmin Adrian Bejan, PhD, Shilin Zhao, PhD, Travis Spaulding, MD, Shannon Stockton, MD, Alexander Silver, Dixon Dorand, MD PhD, Siwei Zhang, PhD, Thomas Stricker, MD PhD, Yaomin Xu, PhD, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 2959.

https://doi.org/10.1182/blood-2019-121513

Published: 2019

Journal Articles

Preliminary Results from a Phase II Study of the Combination of Pevonedistat and Azacitidine in the Treatment of MDS and MDS/MPN after Failure of DNA Methyltransferase Inhibition

Tamara K Moyo, MD PhD, Justin M. Watts, MD, Barry S. Skikne, MD, Jason H. Mendler, MD PhD, Virginia M. Klimek, MD, Sheau-Chiann Chen, PhD, Run Fan, PhD MS, Ingrid A Anderson, PhD, Andrew Sochacki, MD, Stephen A. Strickland, MD, Michael T Byrne, DO, Terrence J Bradley, MD, Gregory D Ayers, MS, Sanjay R Mohan, MD MSCI, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 4236.

https://doi.org/10.1182/blood-2019-130003

Published: 2019

Journal Articles

Next Generation Myelofibrosis Risk Analysis in the Electronic Health Record

Andrew Sochacki, MD, Cosmin Adrian Bejan, PhD, Shilin Zhao, PhD, Travis Spaulding, MD, Thomas Stricker, MD PhD, Yaomin Xu, PhD, Michael R. Savona, MD

Blood (2018) 132 (Supplement 1): 3038.

https://doi.org/10.1182/blood-2018-99-113692

Published: 2018

Journal Articles

Mutational landscape of myelodysplastic/myeloproliferative neoplasm–unclassifiable

Blood (2018) 132 (19): 2100–2103.

https://doi.org/10.1182/blood-2018-05-848473

Published: 2018

Includes: Supplemental data

Journal Articles

Preliminary Results from a Phase I Dose Escalation Trial of Ruxolitinib and the PI3Kδ Inhibitor TGR-1202 in Myelofibrosis

Tamara K Moyo, MD PhD, Andrew Sochacki, MD, Gregory D Ayers, MS, Michael T. Byrne, DO, Stephen A. Strickland, Sanjay R. Mohan, MD, Jill Harrison, Lynne D Berry, Channing V Dudley, Rachel Severs, Laura Dugger, Hari P. Miskin, MS, Amy Cavers, Peter Sportelli, Laura C Michaelis, MD, Ruben A. Mesa, MD, Michael R. Savona, MD

Blood (2016) 128 (22): 1125.

https://doi.org/10.1182/blood.V128.22.1125.1125

Published: 2016

NARROW

Safety, Pharmacodynamic, and Anti-Tumor Activity of SL-172154 As Monotherapy and in Combination with Azacitidine (AZA) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) Patients (pts)

Integrating Mosaic Chromosomal Alterations and Single-Nucleotide Variants to Predict Evolution of Clonal Hematopoiesis

Patient-Specific Risk Factors Independently Influence Survival in Myelodysplastic Syndromes in an Unbiased Review of EHR Records

JAK2 V617F Clonal Hematopoiesis Stratifies By Peripheral Blood Counts.

Patient Specific Comorbidities Impact Overall Survival in Myelofibrosis

Preliminary Results from a Phase II Study of the Combination of Pevonedistat and Azacitidine in the Treatment of MDS and MDS/MPN after Failure of DNA Methyltransferase Inhibition

Next Generation Myelofibrosis Risk Analysis in the Electronic Health Record

Mutational landscape of myelodysplastic/myeloproliferative neoplasm–unclassifiable

Preliminary Results from a Phase I Dose Escalation Trial of Ruxolitinib and the PI3Kδ Inhibitor TGR-1202 in Myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only